Methods
An electronic search of the PubMed database for relevant articles was performed. The following MESH search headings were used: 'oligometastasis', 'oligometastases', 'oligometastatic', 'oligometastatic disease', as well as 'esophageal' and 'esophageal cancer' or 'gastric', 'gastric cancer', 'stomach', and 'stomach cancer'. Reference lists were manually searched for additional articles. Only papers in English and German were included. Beside retrospective studies, review articles and meta-analyses were considered.
Results
The search 'oligometastasis', 'oligometastases', 'oligometastatic', 'oligometastatic disease', 'esophageal', and 'esophageal cancer' delivered: -A single-center study on RFA of lung oligometastases from 5 primary lesions including esophageal cancer (n = 123) [7] . Patients with esophageal cancer had the worst overall survival. -A single-center study on stereotactic radiation of metastases 'from any primary site, metastatic to one to three organ sites' [2] , in which esophageal cancer patients are included in the group 'non-breast cancer'. -A recent review complaining about the lack of data regarding this matter [8] .
The literature included in the current German Guideline [9] contained two retrospective studies reporting no benefit for resection of metastatic esophageal cancer [10, 11] .
The search 'oligometastasis', 'oligometastases', 'oligometastatic', 'oligometastatic disease', 'gastric', 'gastric cancer', 'stomach', and 'stomach cancer' delivered: -A recent case report with review of the current literature [12] . -A single-center study on the effects of concurrent involvedfield radiotherapy and XELOX on oligometastatic recurrence as opposed to chemotherapy alone [13] . The literature included in the current German Guideline [14] contains a systematic review by Shirabe et al. [15] , collecting small retrospective studies on resection of hepatic metastases of gastric cancer.
For both esophageal and gastric cancer, no randomized controlled trial could be found.
Discussion
According to the guidelines of the European Society for Medical Oncology (ESMO), 'patients with metastatic esophageal cancer can be considered for different options of palliative treatment depending on the clinical situation' [9] . Furthermore, the German guidelines do not recommend esophagectomy in the presence of preoperatively diagnosed metastasis. However, the guidelines consent to resect very limited metastatic disease if this is diagnosed first intraoperatively and if the whole tumor can be surgically resected [9] .
Both retrospective studies by Erhunmwunsee et al. [10] and Shimoji et al. [11] are included in the guidelines although resection did not improve the overall survival.
There is no guideline indication concerning the treatment of metachronous distant metastases of esophageal cancer. The decision to resect distant metastases is mostly a personalized treatment recommended by tumor boards for patients in good general condition with a long tumor-free survival. In a small series of 33 patients undergoing pulmonary metastasectomy after definitive treatment of esophageal cancer, however, 70% developed further distant metastases [16] . Thus, it is unclear if these patients significantly profit from the removal of metastases.
Furthermore, to our knowledge, there are currently no commonly accepted prognostic factors of metastatic esophageal cancer indicating a more favorable biologic behavior except gender. Since (especially premenopausal) women with metastatic squamous esophageal cancer seem to have a lower risk of dying from esophageal cancer when compared with men of similar age [17] and (especially the postmenopausal) show a statistically better prognosis of locoregional advanced disease [17] , the female gender might be one of those prognostic factors supporting a more aggressive treatment of these patients.
The situation is similar for metastatic gastric cancer. The present guidelines report a lack of evidence for recommending a curative approach in metastatic gastric cancer. The liver is the most common site for metastases in patients with gastric cancer [18] . The reported rate of liver resection, however, is less than 1% due to the multiple, bilateral, and extrahepatic nature of the disease [15, 19] .
The outcome of treatments other than chemotherapy for hepatic metastatic gastric cancer can be mostly pooled out of a larger group called 'non-colorectal, non-neuroendocrine' (NCRNE) in studies. The 5-year survival after surgical R0 resection seems to be as high as 27-37% [20] [21] [22] . In a retrospective study on 257 patients from 5 Japanese centers, however, 75% of patients had disease recurrence especially in the liver (72.4%) after a median interval of 7 months after resection [23] . A recent meta-analysis of retrospective studies describes a survival benefit, though [19] . Even in gastric cancer with peritoneal carcinomatosis, maximal cytoreductive surgery combined with regional hyperthermic intraperitoneal and systemic chemotherapy seems to achieve prolonged survival in selected patients [24] . However, a retrospective analysis of 5,185 cases from the SEER database which were initially diagnosed with histologically confirmed gastric cancer with distant metastases between 2004 and 2009 showed that both the resection of only the primary tumor and the combined resection of both the tumors and the metastases were independent prognostic factors for survival improvement. The resection of distant metastases, however, did not significantly improve the survival compared to those patients in which only the primary tumor was removed [25] . In a small study on 35 Chinese patients undergoing both resection of the primary tumor and synchronous hepatic metastatic disease, Liu et al. [26] identified lymphovascular invasion of the primary tumor and multiple liver metastases as negative prognostic factors for survival.
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Kadowaki et al. [27] identified previous gastrectomy (odds ratio (OR) = 1.86; p = 0.01), single metastatic site (OR = 1.80; p = 0.03), and normal alkaline phosphatase levels (OR = 2.81; p < 0.01) as independent predictors of long-term survival in patients with metastatic gastric cancer undergoing chemotherapy. These might help to identify the subgroup of patients who might benefit of a most aggressive treatment of metastatic gastric cancer [27] .
Regarding the significance of liver metastasis in upper gastrointestinal cancer, the meta-analysis by Grimes et al. [19] suggests that patients undergoing ablative treatments of synchronous, multiple, or bilobar metastases have a worse survival compared to those who undergo removal of metachronous singular metastases.
The multicenter FLOT3 study with its three-armed design (in locally advanced tumors, tumors with limited metastases, metastatic tumors of the esophagogastric junction and gastric cancer) suggests that well-selected patients may benefit from surgery at the stage of limited metastases [28] . However, there are currently no prognostic factors or biomarkers to identify which patients will benefit.
The FLOT5 study (RENAISSANCE) examines the effect of chemotherapy alone versus chemotherapy followed by surgical resection on survival and quality of life in patients with limited metastatic adenocarcinoma of the stomach or esophagogastric junction. First results are expected in 2021.
Conclusions
Several retrospective analyses suggest that long-term survival is 'better than expected' after ablative treatment of OMD in upper gastrointestinal cancers. However, this effect might not be due to the treatment strategies themselves but rather due to the selection of patients [29] .
There is general agreement that a metachronous isolated oligometastatic relapse in patients with good systemic therapy response can be surgically or interventionally removed. At the moment, the 'test of time' is the most convincing indicator of a more favorable biological cancer behavior. However, there is an increasing shift toward individualized, multidisciplinary management of OMD because it is difficult to conduct randomized controlled trials due to the variety of presentations [5] .
In the absence of prognostic factors for metastatic upper gastrointestinal disease, biomarkers indicating which patients might benefit from a more aggressive surgical or radiological removal of OMD are probably the key to this problem. The presence of circulating tumor cells, for example, seems to correlate with disease progression and survival [30] . Moreover, serum microRNAs could potentially be useful biomarkers [31] . Examples of pro-metastatic microRNAs include microRNA-10b (upregulated in primary metastatic breast cancer) and microRNA-21 (correlates with advanced stage and poor outcomes in breast and pancreatic cancer) [5] .
The 'test of time' in patients with good systemic response might warrant a more aggressive ablative treatment of OMD even in upper gastrointestinal cancer ( fig. 1 ). Until more data are available, OMD in upper gastrointestinal cancer should be managed with an individualized, multidisciplinary approach.
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